ADAP · Insider Trading
Adaptimmune Therapeutics plc American Depositary Shares
Every open-market purchase and sale reported by ADAP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-03 | Gavin Wood | Chief Financial Officer | Sell | −96,000 | −$950 |
| 2025-08-29 | William C Bertrand JR | Chief Operating Officer | Sell | −207,000 | −$2.09K |
| 2025-08-19 | Ali Behbahani | Director | Sell | −19,500,000 | −$229.17K |
| 2025-07-30 | EcoR1 Capital, LLC | 10%+ Owner | Sell | −64,052,538 | −$6.89M |
| 2025-02-20 | Joanna Elizabeth Brewer | Chief Scientific Officer | A | +2,686,728 deriv. | — |
| 2025-02-20 | Adrian Rawcliffe | Chief Executive Officer | A | +8,572,080 deriv. | — |
| 2025-02-20 | Elliot Norry | Chief Medical Officer | A | +2,686,728 deriv. | — |
| 2025-02-20 | Cintia Piccina | Chief Commercial Officer | A | +2,686,728 deriv. | — |
| 2025-02-20 | John Lunger | Chief Patient Supply Officer | A | +2,686,728 deriv. | — |
| 2025-02-20 | William C Bertrand JR | Chief Operating Officer | A | +2,686,728 deriv. | — |
| 2025-01-17 | William C Bertrand JR | Chief Operating Officer | Sell | −5,584 | −$3.24K |
| 2025-01-17 | John Lunger | Chief Patient Supply Officer | Sell | −5,584 | −$3.24K |
| 2025-01-17 | Elliot Norry | Chief Medical Officer | Sell | −5,584 | −$3.24K |
| 2025-01-17 | Adrian Rawcliffe | Chief Executive Officer | Sell | −30,601 | −$17.77K |
| 2025-01-15 | William C Bertrand JR | Chief Operating Officer | Sell | −19,542 | −$11.36K |
| 2025-01-15 | John Lunger | Chief Patient Supply Officer | Sell | −19,542 | −$11.36K |
| 2025-01-15 | Adrian Rawcliffe | Chief Executive Officer | Sell | −59,569 | −$34.64K |
| 2025-01-15 | Elliot Norry | Chief Medical Officer | Sell | −22,195 | −$12.92K |
| 2025-01-15 | Cintia Piccina | Chief Commercial Officer | Sell | −12,991 | −$7.47K |
| 2024-07-01 | Ali Behbahani | Director | A | +1,144,686 deriv. | — |
| 2024-07-01 | Lawrence M Alleva | Director | A | +1,213,926 deriv. | — |
| 2024-07-01 | Priti Hegde | Director | A | +1,144,686 deriv. | — |
| 2024-07-01 | Andrew R Allen | Director | A | +660,000 deriv. | — |
| 2024-07-01 | Garry E Menzel | Director | A | +1,121,604 deriv. | — |
| 2024-07-01 | John Furey | Director | A | +660,000 deriv. | — |
| 2024-07-01 | Kristen Hege | Director | A | +660,000 deriv. | — |
| 2024-07-01 | David M Mott | Director | A | +1,583,214 deriv. | — |
| 2024-06-18 | Cintia Piccina | Chief Commercial Officer | Sell | −24,531 | −$22.81K |
| 2024-03-18 | Cintia Piccina | Chief Commercial Officer | A | +6,219,696 deriv. | — |
| 2024-01-17 | Ali Behbahani | Director | A | +40,950 deriv. | — |
| 2024-01-17 | John Lunger | Chief Patient Supply Officer | A | +3,109,848 deriv. | — |
| 2024-01-17 | Joanna Elizabeth Brewer | Chief Scientific Officer | A | +3,109,848 deriv. | — |
| 2024-01-17 | Elliot Norry | Chief Medical Officer | Sell | −20,563 | −$14.11K |
| 2024-01-17 | Gavin Wood | Chief Financial Officer | A | +3,109,848 deriv. | — |
| 2024-01-17 | Helen Katrina Tayton-Martin | Chief Business & Strgy Officer | A | +3,109,848 deriv. | — |
| 2024-01-17 | William C Bertrand JR | Chief Operating Officer | A | +3,109,848 deriv. | — |
| 2024-01-17 | Adrian Rawcliffe | Chief Executive Officer | A | +9,329,568 deriv. | — |
| 2024-01-17 | Kristen Hege | Director | A | +81,906 deriv. | — |
| 2024-01-17 | William C Bertrand JR | Chief Operating Officer | Sell | −23,589 | −$16.42K |
| 2024-01-17 | Adrian Rawcliffe | Chief Executive Officer | Sell | −39,384 | −$27.59K |
| 2024-01-17 | Elliot Norry | Chief Medical Officer | A | +3,109,848 deriv. | — |
| 2024-01-17 | John Lunger | Chief Patient Supply Officer | Sell | −22,795 | −$15.89K |
| 2024-01-12 | John Lunger | Chief Patient Supply Officer | Sell | −9,229 | −$7.81K |
| 2024-01-12 | William C Bertrand JR | Chief Operating Officer | Sell | −9,229 | −$7.81K |
| 2024-01-12 | Elliot Norry | Chief Medical Officer | Sell | −11,808 | −$10.02K |
| 2024-01-12 | Adrian Rawcliffe | Chief Executive Officer | Sell | −29,202 | −$24.73K |
| 2023-09-01 | Adrian Rawcliffe | Chief Executive Officer | Sell | −2,403 | −$1.87K |
| 2023-08-01 | John Lunger | Chief Patient Supply Officer | Sell | −3,096 | −$2.80K |
| 2023-07-10 | Garry E Menzel | Director | Sell | −47,702 | −$43.45K |
| 2023-07-05 | Priti Hegde | Director | A | +488,586 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| EcoR1 Capital, LLC | 10%+ Owner | 127,805,220 | $7.40M |
| Ali Behbahani | Director | 14,671,794 | $849.50K |
| William C Bertrand JR | Chief Operating Officer | 986,352 | $57.11K |
| Adrian Rawcliffe | Chief Executive Officer | 44,327 | $2.57K |
| Cintia Piccina | Chief Commercial Officer | 18,421 | $1.07K |
| John Lunger | Chief Patient Supply Officer | 7,510 | $435 |
| Elliot Norry | Chief Medical Officer | 7,510 | $435 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADAP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.